Breakthrough therapies: Cystic fibrosis (CF) potentiators and correctors

Publisher： John Wiley & Sons Inc

E-ISSN： 1099-0496|50|S40|S3-S13

ISSN： 8755-6863

Source： PEDIATRIC PULMONOLOGY, Vol.50, Iss.S40, 2015-10, pp. : S3-S13

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Inhaled Interventions in Cystic Fibrosis: Mucoactive and Antibiotic Therapies

By  

Respiration, Vol. 88, Iss. 6, 2014-11 ,pp. : 441-448

Karger

Access to resources Recommend Favorite

Geographic variations in cystic fibrosis: An analysis of the U.S. CF Foundation Registry

By  

PEDIATRIC PULMONOLOGY, Vol. 50, Iss. 8, 2015-08 ,pp. : 754-762

John Wiley & Sons Inc

Access to resources Recommend Favorite

Novel personalized therapies for cystic fibrosis: treating the basic defect in all patients

By  

JOURNAL OF INTERNAL MEDICINE, Vol. 277, Iss. 2, 2015-02 ,pp. : 155-166

John Wiley & Sons Inc

Access to resources Recommend Favorite

Rescue therapy within the UK Cystic Fibrosis Registry: An exploration of predictors of intravenous antibiotic use amongst adults with CF

By  

RESPIROLOGY (ELECTRONIC), Vol. 23, Iss. 2, 2018-02 ,pp. : 190-197

John Wiley & Sons Inc

Access to resources Recommend Favorite

Improving complex medical care while awaiting next‐generation CFTR potentiators and correctors: The current pipeline of therapeutics

By  

PEDIATRIC PULMONOLOGY, Vol. 50, Iss. S40, 2015-10 ,pp. : S66-S73

John Wiley & Sons Inc

Access to resources Recommend Favorite